1. Home
  2. AKRO vs STC Comparison

AKRO vs STC Comparison

Compare AKRO & STC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • STC
  • Stock Information
  • Founded
  • AKRO 2017
  • STC 1893
  • Country
  • AKRO United States
  • STC United States
  • Employees
  • AKRO N/A
  • STC N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • STC Specialty Insurers
  • Sector
  • AKRO Health Care
  • STC Finance
  • Exchange
  • AKRO Nasdaq
  • STC Nasdaq
  • Market Cap
  • AKRO 2.4B
  • STC 2.0B
  • IPO Year
  • AKRO 2019
  • STC N/A
  • Fundamental
  • Price
  • AKRO $32.78
  • STC $72.84
  • Analyst Decision
  • AKRO Strong Buy
  • STC Buy
  • Analyst Count
  • AKRO 7
  • STC 3
  • Target Price
  • AKRO $43.20
  • STC $77.33
  • AVG Volume (30 Days)
  • AKRO 571.1K
  • STC 135.4K
  • Earning Date
  • AKRO 11-08-2024
  • STC 10-23-2024
  • Dividend Yield
  • AKRO N/A
  • STC 2.74%
  • EPS Growth
  • AKRO N/A
  • STC 66.11
  • EPS
  • AKRO N/A
  • STC 2.12
  • Revenue
  • AKRO N/A
  • STC $2,408,952,800.00
  • Revenue This Year
  • AKRO N/A
  • STC N/A
  • Revenue Next Year
  • AKRO N/A
  • STC $15.46
  • P/E Ratio
  • AKRO N/A
  • STC $34.35
  • Revenue Growth
  • AKRO N/A
  • STC 3.34
  • 52 Week Low
  • AKRO $13.47
  • STC $44.05
  • 52 Week High
  • AKRO $37.00
  • STC $76.83
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 60.98
  • STC 59.34
  • Support Level
  • AKRO $32.70
  • STC $70.41
  • Resistance Level
  • AKRO $35.11
  • STC $73.97
  • Average True Range (ATR)
  • AKRO 1.68
  • STC 1.70
  • MACD
  • AKRO 0.19
  • STC 0.60
  • Stochastic Oscillator
  • AKRO 69.07
  • STC 85.45

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About STC Stewart Information Services Corporation

Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments; Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.

Share on Social Networks: